Takeda Pharmaceutical (NYSE:TAK) Hits New 52-Week High - Still a Buy?

Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $15.43 and last traded at $15.38, with a volume of 1228561 shares trading hands. The stock had previously closed at $15.32.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Trading Up 0.4 %

The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The company has a market capitalization of $48.94 billion, a P/E ratio of 38.45, a P/E/G ratio of 0.24 and a beta of 0.26. The company has a 50-day simple moving average of $14.86 and a 200 day simple moving average of $13.98.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Sell-side analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Institutional Investors Weigh In On Takeda Pharmaceutical

A number of institutional investors have recently added to or reduced their stakes in the company. Gallacher Capital Management LLC lifted its position in shares of Takeda Pharmaceutical by 10.5% in the 1st quarter. Gallacher Capital Management LLC now owns 19,493 shares of the company's stock worth $290,000 after acquiring an additional 1,854 shares during the period. Signaturefd LLC raised its stake in shares of Takeda Pharmaceutical by 3.8% in the first quarter. Signaturefd LLC now owns 67,579 shares of the company's stock valued at $1,005,000 after purchasing an additional 2,482 shares in the last quarter. Bleakley Financial Group LLC lifted its position in Takeda Pharmaceutical by 2.6% in the first quarter. Bleakley Financial Group LLC now owns 326,572 shares of the company's stock worth $4,856,000 after purchasing an additional 8,232 shares during the period. Cerity Partners LLC boosted its stake in Takeda Pharmaceutical by 81.7% during the first quarter. Cerity Partners LLC now owns 159,285 shares of the company's stock worth $2,369,000 after buying an additional 71,634 shares in the last quarter. Finally, Allworth Financial LP increased its holdings in Takeda Pharmaceutical by 12.7% in the 1st quarter. Allworth Financial LP now owns 10,797 shares of the company's stock valued at $163,000 after buying an additional 1,215 shares during the period. 9.17% of the stock is owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.